Publications
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
New England Journal of Medicine
June 16, 2021
The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.
This study evaluates the range and severity of neurologic involvement among children and adolescents associated with COVID-19.
.png)
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
Journal of the American Medical Association
February 24, 2021
This case series uses national coronavirus disease 2019 (COVID-19) registry data to describe the epidemiology, clinical characteristics, complications, and hospital and postdischarge outcomes of pediatric patients with multisystem inflammatory syndrome in children (MIS-C) and to compare each in patients with severe COVID-19.
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
New England Journal of Medicine
June 29, 2020
Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children and its temporal association with coronavirus disease 2019 is important, given the clinical and public health implications of the syndrome.